Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 184 |
| Active Pipeline (Recruiting Now) | 126 (59) |
| Completed vs Stopped Early | 7 / 2 (1.1%) |
| Median Closed Actual Enrollment | 30 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Ruijin Hospital | Shanghai | 44 |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality | 31 |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality | 28 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04208347 | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | Phase II/III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Ruijin Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.